About Henlius-Honor

Honor

2024

Pharmcube 2023 Top 15 Business Development Innovators in China
2024

Outstanding Contributions to Economy
2024

2024 Shanghai Top 100 Hard Tech Companies List
2024

2024 Shanghai Top 100 Most Promising SME Brands
2023

2022 Health Communication - Social Responsibility Award
2023

Outstanding Contribution Award for Private Enterprise in Xuhui District
2023

Top 10 Most Influential Antibody Company in 2023
2023

2022 Chinese Innovative Antibody Company Top 30
2023

BioCon Awards - Biopharmaceutical Enterprise Star in 2022
2023

2022 Shanghai Biopharmaceutical "New Excellent Medical Device" Product Catalog
2023

2022 China Pharmaceutial Social Responsility Media Watch-Public Welfare Pillar
2023

Brand of High-Quality Pharmaceutical Development Achievements in China
2023

Enterprise of High-Quality Pharmaceutical Development Achievements in China
2023

Shanghai Drug Manufacturer Credit Assessment Grade A in 2022
2023

2022 Outstanding Scientific Innovation Enterprise Award and Top100 Enter-prises of Contribution Award
2023

Advanced Unit for Harmonious Creation in 2022
2023

The Gold Walking Stick Award 「Top 10 Innovative Pharmaceutical Enterprises in 2022」
2023

2022 Wind ESG Hong Kong Stock Best Practice Award
2022

2022 The 18th China Golden Awards For Excellence In Public Relations
2022

HR Asia Best Companies to Work For in Asia 2022
2022

2022 JRJ GoldenWis Award
2022

2022 The Reputation list of China Listed Companies
2022

The 7th "Jin Gang Stocks" Most Valuable Pharmaceutical and Medical Company
2022

2022 Guruclub Greater China Best Listed Company Awards
2022

2022 Innovative Product Award - HANSIZHUANG
2022

Certificate of For Good Enterprise
2022

2022 Golden Flag Award - Public Relations
2022

2022 Changchun Award –「Pharmaceutical R&D Enterprise of the Year」
2022

Business Development of the Yea
2022

2022 Top100 Chinese Pharmaceutical Innovative Enterprises
2022

Pudong New Area District R&D Institution Enterprise
2022

Top Ten Public Welfare Enterprises of "China Health Public Welfare Star" in 2021
2022

Ranked 10th in Top 15 Biotechs of the 9th Hong Kong Stocks Top 100 Biotech List
2022

The 27th of Shanghai Enterprise Technology Centers
2022

The 6th "Jin Gang Stocks" Most Valuable Pharmaceutical and Medical Company
2021

The 4th ONE FOSUN Charity Week 2021 “Top Ten Charity Projects”
2021

Shanghai Drug Manufacturer Credit Rating A in 2021
2021

2021 "Jinzhi Award" Excellent Business Practice Award in China Biopharmaceutical Industry
2021

Top 10 Independent Innovation of Shanghai High-tech Achievement Transformation Project
2021

2021 Top 100 Chinese Pharmaceutical Innovation Companies, the First Tier
2021

Pudong New District Strong-growth Compnay
2021

Golden Flag Award for CSR
2021

2021 Changchun Award
2021

The 17th China Golden Awards for Excellence in PR
2021

The Hong Kong Management Association "Certificate of Excellence in ESG Reporting"
2021

Innovation Billboard "The Best Business Development"
2021

Shanghai Worker Pioneer 汉曲优 Core Project Team
2021

Chinese Antibody Drug Enterprise Top 30 Innovation Star in 2020
2021

SPPA "Famous and Excellent Products in 2020" - 汉利康 Rituximab & 汉曲优 Trastuzumab
2021

MENET "2020 TOP20 China Biopharmaceutical Company"
2021

Red Cross Society of China Fujian Branch "Honor Certificate for Charity"
2021

National Worker Pioneer (Henlius HLX01 - Project Core Team)
2021

Global Health & Pharma Magazine "Most Innovative Global Biopharmaceutical Company 2021"
2021

Shanghai Anti-tumour Biologic Engineering and Technology Research Centre
2021

The 13th China Health Annual Forum Top 10 New Medicine(汉曲优®)
2020

Shanghai Model Group
2020

5th Social Value Co-creation Outstanding Award
2020

Gelonghui "2020 The Best Listing Company - Best Information Disclosure Award"
2020

CIPRA "The 16th China Global Awards for Excellence in Public Relations Social Responsibility Bronze Award"
2020

eMedClub PharmaBIGStar - "Top 50 Most Innovative Companies of Chinese Biomedicine in 2020"
2020

JRJ.COM "Jinzhi Award - The Most Valued Top 10 in Biopharmaceutical Industry"
2020

CNPIIC "China Innovation New Power in Pharmaceutical Industry"
2020

Changchun Award "2020 Innovative Pharmaceutical Enterprise"
2020

China Pharmaceutical Brand with Greatest Growth Potential - 汉利康® HLX01 Rituximab Injection
2020

2019 China Biopharmaceutical Company Top 20
2020

EBC Awards "The Most Influential Enterprise in Biopharmaceutical Industry"
2020

China Youth "2019 PR Influence Top 20 Startup in Pharmaceutical Industry"
2019

ZJ Science City "Outstanding Listed Company"
2019

The 4th Jin Gang Gu "The Most Valuable Pharmaceutical Enterprise"
2019

The 8th Charity Festival "Innovative CSR Activity Award"
2019

Sina Medical - Wisdom Growing Forum "The Most Valued Biopharmaceutical Enterprise"
2019

Sina Medical - Wisdom Growing Forum "The Best Charity Event in BioPharm Industry"
2019

Vcbeat Net "Future Healthcare VB 100"
2019

ONE FOSUN CSR Week "Special CSR Activity - Understanding Lymphoma: A Medical Education Charity Event"
2019

Global Generics & Biosimilars Awards "Company of the Year,Asia Pacific - Finalist"
2019

Global Generics & Biosimilars Awards 2019 "Biosimilar Initiative of the Year" - 汉利康^®
2019

ZCCS "The Most Innovative Award"
2019

Equal Ocean "China Healthcare Industry Award - the Best Innovative Biopharmaceutical Enterprise"
2019

Frost & Sullivan "China New Economy Award - Excellence in Innovation"
2019

MENET, Medicine Economic Reporter "Top 20 Biopharmaceutical Company in China"
2019

The 8th China Finance Summit "The Most Innovative Enterprise"
2019

Trade Union of Xuhui District, Science and Technology Commission of Xuhui District "2019 Xuhui District Innovation Centre for Science & Technology Contest Finalist"
2023

2022 Health Communication - Creative Award
2019

China Financial Market "Excellent Biopharmaceutical Enterprise"
2019

Forbes China "The Most Innovative Companies in China"
2019

JRJ.com "Future Company of BioPharm Industry"
2019

Shanghai Worker Pioneer HLX01 Core Project Team
2018

Sina Medical "The Most Innovative Enterprise in Pharmaceutical Industry in 2018 China"
2018

Social Responsibility Conference "2018 Branding Award"
2018

Chinese Pharmaceutical Association "The Fast-growing Pharmaceutical Enterprise of Science and Technology Innovation in 2018"
2018

Ernst & Young "The Most Promising Enterprises in China"
2018

Vcbeat Net "Top of 2018 Future Medicine 100"
2018

Venture 50 "China Top 50 Investments for Value "
2018

China Business Journal "The Most Innovative Enterprise in Health Industry"
2018

The 7th China Finance Summit "The Most Innovative Enterprise"
2018

China Entrepreneur "Future Stars"
2018

Science and Technology Innovation Award for Songjiang Manufacturing Facility
2018

China Healthcare Consulting Group(CHC)-CITIC Securities "2017 Top Venture in Medical and Health"
2018

Life Science & Healthcare Unicorn Enterprise in Pudong New Area, Shanghai
2018

Innovative Startup Top 20 in Pudong New Area
2018

Haoyue Capital "Annual Best Venture Case in Biopharm "
2018

IMAPAC "Bioprocessing Innovations in Single-use Manufacturing in China"
2018

BioPharma "Asia Biotech of 2017"
2017

Life Science & Healthcare Unicorn Enterprise in China
2017

Deloitte Touche Tohmatsu "2017 Future Star in the China Pharma Industry"
2017

IMAPAC "Leading Innovations in Cutting-edge Technologies for Novel mAb Development & Production"
2017

IMAPAC "Best Bioprocessing Excellence in China"
2017

Specialized & Innovative SME
2016

Hign and New Technology Enterprises

R&D Project

2021

Shanghai Anti-tumour Biologic Medicine Engineering and Technology Research Centre
2020

National Major R&D Program "Public Security All-risk Prevention & Control and Emergency Technical Equipment" —— COVID-19 Project
2020

Xuhui Enterprise Technology Research Center
2020

Postdoctoral Education Station in Pudong New Area
2020

Shanghai Major Construction Projects and Shanghai Strategic Emerging Industry Projects (Songjiang Manufacturing Facility)
2020

National Technology Transformation Project (Songjiang Manufacturing Facility)
2019

National Science and Technology Major Project in the 13th Five-year Plan of China —— Major New Drug Research & Development Project
2019

Songjiang Manufacturing Facility Listed among Shanghai Strategic Emerging Projects
2018

Research & Development Enterprise in Pudong New Area
2018

National Science and Technology Major Project in the 13th Five-year Plan of China —— Major New Drug Research & Development Project
2018

Shanghai Technology Giant Enterprise
2018

Shanghai Industry Transformation and Upgrade Program —— Projects to Build a Robust Foundation for Industrial Development
2017

Specialised & Innovative SME
2016

High and New Technology Enterprises
2015

Shanghai Industry Transformation and Upgrade Program (Xuhui Manufacturing Facility)
2012

National Science and Technology Major Project in the 12th Five-year Plan of China —— Major New Drug Research & Development Project
2011

National Science and Technology Major Project in the 12th Five-year Plan of China —— Major New Drug Research & Development Project

304am永利集团|·主頁(歡迎您)